A phase II study of rebeccamycin analog (NSC-655649) in metastatic renal cell cancer

Investigational New Drugs

Volumn 21, Issue 4, 2003, Pages 465-471

  Hussain, Maha ^a,c   Vaishampayan, Ulka ^a   Heilbrun, Lance K ^a   Jain, Vikash ^a   LoRusso, Patricia M ^a   Ivy, Percy ^b   Flaherty, Lawrence ^a  

^a WAYNE STATE UNIVERSITY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

Chemotherapy; Rebeccamycin; Renal cell carcinoma

Indexed keywords

1,11 DICHLORO 6 (2 DIETHYLAMINOETHYL) 12,13 DIHYDRO 5H INDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE 5,7(6H) DIONE 13 (4 O METHYLGLUCOSIDE); REBECCAMYCIN;

ADULT; AGED; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER REGISTRY; CANCER SURVIVAL; CAUCASIAN; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; ERYTHROCYTE; ERYTHROCYTE CONCENTRATE; FATIGUE; FEMALE; FOLLOW UP; HUMAN; HYPONATREMIA; IMMUNOTHERAPY; KIDNEY CARCINOMA; LYMPHOCYTOPENIA; MALE; MEDICAL ASSESSMENT; METASTASIS; NAUSEA; NEPHRECTOMY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT DISEASE; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; AMINOGLYCOSIDES; CARBAZOLES; CARCINOMA, RENAL CELL; CONFIDENCE INTERVALS; FEMALE; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; SURVIVAL RATE;

EID: 1642575350     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1026259503954     Document Type: Article

References (12)

1. Motzer RJ, Mazumdar M, Bacik J, et al.: Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17(18): 2530-2540
2. Bukowski RM: Natural history and therapy of metastatic renal cell carcinoma. The role of interleukin-2. Cancer 80: 1198-1220, 1997
3. Kaneko T, Wong H, Utzig J, Schurig J, Doyle T: Water soluble derivatives of rebeccamycin. J Antibiot (Tokyo) 43(1): 125-127, 1990
4. Krishnan BS, Moore ME, Lavoie CP, Long BH, Dalterio RA, Wong HS, Rosenberg IE: Fluorescence polarization studies of the binding of BMS 181176 to DNA. J Biomol Struct Dyn 12(3): 625-636, 1994
5. Merchant J, Tutsch K, Dresen A, Arzoomanian R, Alberti D, Feierabend C, Binger K, Marnoccha R, Thomas J, Cleary J, Wilding G: Phase I clinical and pharmacokinetic study of NSC 655649, a rebeccamycin analogue, given in both single-dose and multiple-dose formats. Clin Cancer Res 8(7): 2193-2201, 2002
6. Tolcher AW, Eckhardt SG, Kuhn J, Hammond L, Weiss G, Rizzo J, Aylesworth C, Hidalgo M, Patnaik A et al.: Phase I and pharmacokinetic study of NSC 655649, a rebeccamycin analog with topoisomerase inhibitory properties. J Clin Oncol 19(11): 2937-2947, 2001
7. Dowlati A, Hoppel CL, Ingalls ST, Majka S, Li X, Sedransk N, Spiro T et al.: Phase I clinical and pharmacokinetic study of rebeccamycin analog NSC 655649 given daily for five consecutive days. J Clin Oncol 19(8): 2309-2318, 2001
8. Fleming TR: One-sample multiple testing procedure for Phase II clinical trials. Biometrics 38: 143-151, 1982
9. Casella G: Refining binomial confidence intervals. Canadian J Statst 14: 113-129, 1987
10. Mehta C, Patel N: StatXact 5: Statistical Software for Exact Nonparametric Inference, User Manual. Cytel Software Corporation, Cambridge, MA 1999, pp. 429-433
11. Lee ET: In: Statistical Methods for Survival Data Analysis, 2nd edn. New York, Wiley & Sons Inc., 1992, pp. 77-78
12. Minasian LM, Motzer RJ, Gluck L et al.: Interferone alfa-2a in advanced RCC: treatment results and survival in 159 patients with long-term follow-up. J Clin Oncol 11: 1368-1375, 1993